S&P 500   3,000.47 (+1.16%)
DOW   27,075.06 (+1.07%)
QQQ   193.82 (+1.43%)
AAPL   235.96 (+0.04%)
FB   189.31 (+3.29%)
MSFT   141.59 (+1.46%)
GOOGL   1,245.78 (+2.30%)
AMZN   1,774.42 (+2.19%)
NVDA   196.91 (+5.56%)
MU   46.52 (+3.70%)
BABA   175.01 (+2.25%)
GE   8.87 (+1.60%)
AMD   30.76 (+0.75%)
T   37.94 (+1.25%)
F   9.08 (+2.83%)
ACB   3.81 (+8.55%)
PRI   123.64 (+1.79%)
NFLX   283.80 (-0.61%)
BAC   29.96 (+2.78%)
GILD   65.57 (+1.63%)
DIS   130.41 (+0.55%)
S&P 500   3,000.47 (+1.16%)
DOW   27,075.06 (+1.07%)
QQQ   193.82 (+1.43%)
AAPL   235.96 (+0.04%)
FB   189.31 (+3.29%)
MSFT   141.59 (+1.46%)
GOOGL   1,245.78 (+2.30%)
AMZN   1,774.42 (+2.19%)
NVDA   196.91 (+5.56%)
MU   46.52 (+3.70%)
BABA   175.01 (+2.25%)
GE   8.87 (+1.60%)
AMD   30.76 (+0.75%)
T   37.94 (+1.25%)
F   9.08 (+2.83%)
ACB   3.81 (+8.55%)
PRI   123.64 (+1.79%)
NFLX   283.80 (-0.61%)
BAC   29.96 (+2.78%)
GILD   65.57 (+1.63%)
DIS   130.41 (+0.55%)
Log in

Rigel Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RIGL)

$1.68
+0.02 (+1.21 %)
(As of 10/15/2019 02:56 PM ET)
Today's Range
$1.66
Now: $1.68
$1.69
50-Day Range
$1.61
MA: $1.71
$1.85
52-Week Range
$1.60
Now: $1.68
$3.29
Volume899,433 shs
Average Volume1.46 million shs
Market Capitalization$280.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.35
Rigel Pharmaceuticals, Inc, a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RIGL
CUSIP76655960
Phone650-624-1100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$44.51 million
Book Value$0.66 per share

Profitability

Net Income$-70,480,000.00

Miscellaneous

Employees158
Market Cap$280.75 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.


Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its quarterly earnings data on Tuesday, August, 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. The biotechnology company had revenue of $10.41 million for the quarter, compared to analyst estimates of $9.25 million. Rigel Pharmaceuticals had a negative net margin of 89.34% and a negative return on equity of 60.72%. During the same period in the previous year, the business earned ($0.16) EPS. View Rigel Pharmaceuticals' Earnings History.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Rigel Pharmaceuticals.

What price target have analysts set for RIGL?

3 analysts have issued twelve-month price objectives for Rigel Pharmaceuticals' stock. Their forecasts range from $7.00 to $8.00. On average, they expect Rigel Pharmaceuticals' share price to reach $7.33 in the next twelve months. This suggests a possible upside of 339.1% from the stock's current price. View Analyst Price Targets for Rigel Pharmaceuticals.

What is the consensus analysts' recommendation for Rigel Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rigel Pharmaceuticals.

What are Wall Street analysts saying about Rigel Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (8/10/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and $7 PT on Rigel following results from the period ended 3/31/2019. During the quarter, Rigel reported sales of $8.1 million for TAVALISSE for the treatment of immune thrombocytopenia (ITP), which was a slight beat vs. our $7.7 million estimate. Our near-term focus for Rigel will remain on quarterly U.S. sales for TAVALISSE. Additionally, we await an EU approval decision by year-end 2019, which could expand the revenue opportunity for Rigel and provide upfront capital of nearly $40 million from Grifols (GRFS – NC)." (5/7/2019)
  • 3. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating though are increasing our price target to $8 from $7.50. The primary drivers to our price target change include: (1) adjustment to base year; and (2) adjustment to fully diluted share count. Our valuation is currently driven wholly by fostamatinib (Tavalisse) with 77% contribution from our U.S. and E.U. projections for cIPT and 23% contribution from our U.S. and E.U. projections for AIHA." (1/23/2019)

Has Rigel Pharmaceuticals been receiving favorable news coverage?

News stories about RIGL stock have been trending neutral recently, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rigel Pharmaceuticals earned a news sentiment score of 0.4 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Rigel Pharmaceuticals.

Are investors shorting Rigel Pharmaceuticals?

Rigel Pharmaceuticals saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 11,630,000 shares, a decrease of 9.2% from the August 30th total of 12,810,000 shares. Based on an average daily volume of 1,250,000 shares, the days-to-cover ratio is currently 9.3 days. Approximately 7.1% of the shares of the company are sold short. View Rigel Pharmaceuticals' Current Options Chain.

Who are some of Rigel Pharmaceuticals' key competitors?

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include Rite Aid (RAD), Terra Tech (TRTC), Synergy Pharmaceuticals (SGYP), Geron (GERN), Inovio Pharmaceuticals (INO), Novavax (NVAX), Verastem (VSTM), Athersys (ATHX), Catalyst Pharmaceuticals (CPRX) and Ocular Therapeutix (OCUL).

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the folowing people:
  • Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 58)
  • Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 54)
  • Dr. Anne-Marie S. Duliege, Exec. VP & Chief Medical Officer (Age 60)
  • Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 58)
  • Dr. Thomas A. Raffin, Co-Founder (Age 72)

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $1.67.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $279.91 million and generates $44.51 million in revenue each year. The biotechnology company earns $-70,480,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. Rigel Pharmaceuticals employs 158 workers across the globe.View Additional Information About Rigel Pharmaceuticals.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is http://www.rigel.com/.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]


MarketBeat Community Rating for Rigel Pharmaceuticals (NASDAQ RIGL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  361 (Vote Outperform)
Underperform Votes:  274 (Vote Underperform)
Total Votes:  635
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe RIGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RIGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel